Kwasi Adu-Berchie

Kwasi Adu-Berchie

Auto-generated profile, based on publicly available information

Kwasi Adu-Berchie

John A. Paulson School of Engineering and Applied Sciences Harvard University Cambridge Massachusetts USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2023 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
KAKwasi Adu-Berchie
Kwasi Adu-Berchie
YLYutong Liu
Yutong Liu
DZDavid K. Y. Zhang
David K. Y. Zhang
BFBenjamin R. Freedman
Benjamin R. Freedman
JBJoshua M. Brockman
Joshua M. Brockman
DMDavid J. Mooney
David J. Mooney

11 July 2022 in Nature Materials
Verified
Journal Article
Closed access
PDF file
KVKyle Vining
Kyle Vining
AMAnna E. Marneth
Anna E. Marneth
KAKwasi Adu-Berchie
Kwasi Adu-Berchie
JGJoshua M. Grolman
Joshua M. Grolman
CTChristina M. Tringides
Christina M. Tringides
DMDavid J. Mooney
David J. Mooney

31 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
DZDavid K. Y. Zhang
David K. Y. Zhang
KAKwasi Adu-Berchie
Kwasi Adu-Berchie
SISiddharth Iyer
Siddharth Iyer
YLYutong Liu
Yutong Liu
NCNicoletta Cieri
Nicoletta Cieri
DMDavid J. Mooney
David J. Mooney
Patient responses to autologous CD19 chimeric antigen receptor (CAR) T-cell therapies are limited by insufficient and inconsistent cellular functionality. Here, we show that controlling the precise level of stimulation during T-cell activation to accommodate individual differences in the donor cells will dictate the functional attributes of CAR-T cell products. The functionality of CAR-T cell products, consisting of a diverse set of blood samples derived from healthy donors, acute lymphoblastic leukemia (ALL), and chronic lymphocytic lymphoma (CLL) patient samples, representing a range of patient health status, is tested upon culturing on artificial antigen-presenting cell scaffolds to deliver T-cell stimulatory ligands (anti-CD3/anti-CD28) at highly defined densities. A clear relationship is observed between the dose of stimulation, the phenotype of the T-cell blood sample prior to T-cell activation, and the functionality of the resulting CAR-T cell products. We present a model, based on this dataset, that predicts the precise stimulation needed to manufacture a desired CAR-T cell product, given the input T-cell attributes in the initial blood sample. These findings demonstrate a simple approach to enhance CAR-T functionality by personalizing the level of stimulation during T-cell activation to enable flexible manufacturing of more consistent and potent CAR-T cells.

15 June 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
KAKwasi Adu-Berchie
Kwasi Adu-Berchie
JBJoshua M. Brockman
Joshua M. Brockman
YLYutong Liu
Yutong Liu
TTTania W. To
Tania W. To
DZDavid K. Y. Zhang
David K. Y. Zhang
DMDavid J. Mooney
David J. Mooney
Although adoptive T cell therapy provides the T cell pool needed for immediate tumor debulking, the infused T cells generally have a narrow repertoire for antigen recognition and limited ability for long-term protection. Here, we present a hydrogel that locally delivers adoptively transferred T cells to the tumor site while recruiting and activating host antigen-presenting cells with GMCSF or FLT3L and CpG, respectively. T cells alone loaded into these localized cell depots provided significantly better control of subcutaneous B16-F10 tumors than T cells delivered through direct peritumoral injection or intravenous infusion. T cell delivery combined with biomaterial-driven accumulation and activation of host immune cells prolonged the activation of the delivered T cells, minimized host T cell exhaustion, and enabled long-term tumor control. These findings highlight how this integrated approach provide both immediate tumor debulking and long-term protection against solid tumors, including against tumor antigen escape.

29 May 2024 in Advanced Materials
Verified
Journal Article
Closed access
JLJunzhe Lou
Junzhe Lou
CMCharlotte Meyer
Charlotte Meyer
EVEinat B. Vitner
Einat B. Vitner
KAKwasi Adu‐Berchie
Kwasi Adu‐Berchie
MDMason T. Dacus
Mason T. Dacus
DMDavid J. Mooney
David J. Mooney

3 June 2024 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
DZDavid K. Y. Zhang
David K. Y. Zhang
JBJoshua M. Brockman
Joshua M. Brockman
KAKwasi Adu-Berchie
Kwasi Adu-Berchie
YLYutong Liu
Yutong Liu
YBYoav Binenbaum
Yoav Binenbaum
DMDavid J. Mooney
David J. Mooney